IMU (ASX) Why IMU is a multi multi bagger

Originally posted by davybabyk: ↑

Hi Wells

It's a good question.

The most recent data - to the ASCO GI Conference in January - had data up to Cohort 3 (3 x 10⁷or 30 million PFU).

I would expect them to be presenting data to Cohort 4 at least - ie 1 x 10⁸ (100 million) PFU for the monotherapy arm.

I think it is too early for initial data from the first monotherapy patients at Cohort 5 - 3 x 10⁸ (300 million) PFU - because they only dosed the first of the Cohort 5 patients on 16 Jan (IT) and 18 Jan (IV). Those patients would have had their 42nd day SPECT scans due on 27 and 29 March and even if those scans did happen on that schedule, I don't think that gives them enough time for evaluation and 3rd party review of their data.

I might be wrong - but it would be an impressive rush job to update their presentation with early Cohort 5 data by 9 April, and it would only be very early data for those first 2 Cohort 5 patients.

Even if they achieved that, I think what will be far more interesting is the longer term data for Cohort 3 and 4 patients - across all cancer types included in the trial. Remember that the 19 Jan presentation was focussed only on the 7 Gastro-intestinal cancer patients. There was an official announcement by the company on 15 Jan, to coincide with the ASCO conference, which gave us a summary of the wider data set. As of that date they had efficacy data for 31 patients and they gave us some information on the wider group, but it was very limited.

This presentation should give us a lot more detail - similar to the level of detail we saw in the November data. Given the pseudo progression issue, I think we can reasonably hope to see a significant increase in the number of responders, with patients who were initially classed as "stable disease" now seeing a major reduction in their tumours (partial response) or maybe even an elimination - complete response. We may also see a "cluster" of good response in a specific cancer type - which would point to the next likely expansion cohort and maybe a second Fast Track designation from the FDA. For example - the 15 Jan Ann mentioned two PR results in Melanoma. If they had more of those, and/or if the two previous "Partial Response" patients improved to Complete Response, then we might see Melanoma highlighted as a target for Fast Track.

I understand the "sick in the guts nervous" feeling, friend Wells. Apart from worry about your investment I know you had a personal cancer scare not long ago. I suspect most of us here have very strong personal reasons for wanting to see IMU succeed with Vaxinia (and with other platforms), quite apart from the reasonable desire for investment success. All I can advise is - go easy on the Easter chocolate, mate!!

Myself, I felt more anxious ahead of the November data release. I think that data - and the extra info in January - can give us strong confidence that Vaxinia does "work" - and that it has remarkable safety and tolerability as well. What remains to be seen is the breadth and depth of the efficacy, and the upcoming data will start to give us a better indication of that. I'm also mindful of the fact that we are still in dose escalation mode - so whatever the data says this time, it is likely that the next data set again - at 10⁸ (100 million) PFU is likely to be even better.

I have focussed my comments on the Monotherapy arms, but we should also be getting the first results for the Combo therapy with Pembrolizumab - probably at 3 x 10⁷or 30 million PFU. That could also be extremely interesting.

Thanks for the question - and best wishes to all

Dave

Expand

Hi Dave
Thanks for your contrinuing contributions .
As regards your latest post today , can I ask you to expand on your thoughts on this last para :
"I have focussed my comments on the Monotherapy arms, but we should also be getting the first results for the Combo therapy with Pembrolizumab - probably at 3 x 10⁷or 30 million PFU. That could also be extremely interesting."
If there are further positive signs that the "combo therapy " with Keytruda , does this not do two things :
1) Push the buttons with the FDA , to further fastrack IMU's pathway(s) for apprioval ??
2) Push the buttons of Merck , who licence / manufacture Keytruda , to form a stronger partnership with IMU ??
My grasp on IMU is nowhere near as broad as yours ..so this might appear to be a naive question , and a "step >back "from IMU''s main aims to be unique in its canncer treatment pathways ...and therefore would be grateful for your additional thoughts on this aspect .
cheers

No.	Vol.	Price($)
1	2000	45.0¢

No.

Vol.

Price($)

2000

45.0¢

Price($)	Vol.	No.
42.0¢	1177	1

Price($)

Vol.

No.

42.0¢

1177

No.	Vol.	Price($)
1	2000	0.450
1	1767	0.445
2	17354	0.440
1	1174	0.435
11	18788	0.430

No.

Vol.

Price($)

2000

0.450

1767

0.445

17354

0.440

1174

0.435

18788

0.430

Price($)	Vol.	No.
0.420	1177	1
0.425	597	1
0.430	350	1
0.435	16517	2
0.440	787	3

Price($)

Vol.

No.

0.420

1177

0.425

597

0.430

350

0.435

16517

0.440

787

(20min delay)
Last 42.5¢		Change 0.000(0.00%)		Mkt cap ! $93.34M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Why IMU is a multi multi bagger, page-22200

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

ASX Market Close: Iron ore prices stay strong; US CPI data due Tues night

Inside the depths of Panasqueira: A legacy carved in rock

'Defining moment' for Unico as miner expands Joaquin's mineralised footprint

Last hurdle for Anson's Green River plant as Korean partner looks over brine

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why IMU is a multi multi bagger, page-22200

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

ASX Market Close: Iron ore prices stay strong; US CPI data due Tues night

Inside the depths of Panasqueira: A legacy carved in rock

'Defining moment' for Unico as miner expands Joaquin's mineralised footprint

Last hurdle for Anson's Green River plant as Korean partner looks over brine

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News